ON MAY 10, 2007, the U.S. Food and Drug Administration held a nine-hour meeting over potential labeling changes for Aranesp, Amgen's best-selling drug, used to treat chemotherapy-induced anemia. Restrictions could annihilate sales at the Thousand Oaks, Californiabased biotechnology giant. Early the next morning hedge